keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28815189/a-case-of-pulmonary-vein-thrombosis-associated-with-treatment-of-omalizumab
#1
Sandhya Narukonda, Nagadarshini Ramagiri Vinod, Medha Joshi
Pulmonary vein thrombosis (PVT) is a challenging diagnosis and has been described in association with or as a complication of pulmonary tumors, lung surgeries, atrial myxoma, and after radiofrequency catheter ablation for atrial fibrillation. There are not many reported cases of PVT associated with medication use. We present a case of a 53-year-old male with a history of severe persistent asthma on omalizumab, who presented with shortness of breath and was found to have PVT on computed tomography scan of the chest...
July 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28815007/appropriate-selection-for-omalizumab-treatment-in-patients-with-severe-asthma
#2
Leo Nygaard, Daniel Pilsgaard Henriksen, Hanne Madsen, Jesper Rømhild Davidsen
Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse. Objective: We aimed to estimate whether potential omalizumab candidates were appropriately selected according to guidelines, and the clinical effect of omalizumab treatment over time. Design: We performed a retrospective observational study on adult patients with asthma treated with omalizumab during 2006-2015 at the Department of Respiratory Medicine at Odense University Hospital (OUH), Denmark...
2017: European Clinical Respiratory Journal
https://www.readbyqxmd.com/read/28802075/overcoming-severe-adverse-reactions-to-venom-immunotherapy-by-using-anti-ige-antibodies-in-combination-with-a-high-maintenance-dose
#3
Eva Stretz, Eva Maria Oppel, Räwer Helen-Caroline, René Chatelain, Sebastian Mastnik, Bernhard Przybilla, Franziska Ruëff
BACKGROUND: An omalizumab treatment and a high maintenance venom dose may both help to prevent recurrent systemic allergic reactions (SAR) to venom immunotherapy (VIT). The effectiveness of this combination therapy, however, is unclear. OBJECTIVE: We wanted to explore the possibility whether a temporary treatment with the anti-IgE antibody omalizumab, combined with a VIT using an elevated maintenance dose of >100 μg venom may establish a permanent tolerance of maintenance VIT...
August 12, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28800272/omalizumab-in-non-allergic-asthma-a-report-of-13-cases
#4
Zeynep Çelebi Sözener, Ömür Aydın, Zeynep Mısırlıgil, Dilşad Mungan, Yavuz Selim Demirel, Gülfem E Çelik, Betül A Sin, Sevim Bavbek
BACKGROUND: There are limited data regarding the effectiveness of omalizumab in patients with non-allergic asthma. OBJECTIVE: To evaluate the clinical and functional effectiveness of omalizumab in patients with non-allergic asthma. METHODS: The study was a single-center, retrospective chart review of patients with non-allergic asthma who were treated with add-on omalizumab between February 2014 and March 2016. After omalizumab was started, data of the Asthma Control Test(ACT), pulmonary function test, and daily oral corticosteroid(OCS) dosage were collected at baseline, 16 weeks, 1 year, 2 and 3 years (if available)...
August 11, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28797731/anaphylaxis-associated-with-omalizumab-administration-risk-factors-and-patient-characteristics
#5
Phillip L Lieberman, Ilisten Jones, Richa Rajwanshi, Karin Rosén, Dale T Umetsu
No abstract text is available yet for this article.
August 7, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28782296/combining-anti-ige-with-oral-immunotherapy
#6
REVIEW
Chunrong Lin, Ivan T Lee, Vanitha Sampath, Chitra Dinakar, Rosemarie H DeKruyff, Lynda C Schneider, Kari C Nadeau
Food allergy is a significant medical problem that affects up to 8% of children in developed countries. At present, there are no curative therapies available in routine practice and management of food allergy involves strict allergen avoidance, education, and prompt treatment upon accidental exposure. Oral immunotherapy (OIT) is an efficacious experimental approach to food allergy and has been shown to provide a substantial benefit in terms of allergen desensitization. However, OIT is associated with high rates of allergic reactions, and the period of protection offered by OIT appears to be limited and highly variable...
August 7, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28780220/clinical-aspects-of-oral-immunotherapy-for-the-treatment-of-allergies
#7
REVIEW
Noriyuki Yanagida, Sakura Sato, Motohiro Ebisawa
Studies on oral immunotherapy (OIT) have been increasing worldwide. Nevertheless, some concerns exist with this treatment. The rate of long-term sustained unresponsiveness is quite low; moreover, the desensitization or sustained unresponsiveness does not equate to tolerance. Furthermore, adverse reactions are frequent. Therefore, safe and feasible methods for long-term therapies are needed. Novel therapies such as low-dose OIT, hypoallergenic products, and OIT in combination with omalizumab are reported as effective for inducing sustained unresponsiveness and may lead to fewer adverse reactions than standard OIT...
August 2, 2017: Seminars in Immunology
https://www.readbyqxmd.com/read/28770635/natural-history-and-treatment-of-cutaneous-and-systemic-mastocytosis
#8
Michelle Le, Barbara Miedzybrodzki, Tim Olynych, Hugo Chapdelaine, Moshe Ben-Shoshan
INTRODUCTION: Mastocytosis, a heterogeneous group of disorders, is characterized by an abnormal increase in the number of mast cells that is limited to the skin (cutaneous mastocytosis), involving extracutaneous tissues (systemic mastocytosis), or presenting as solid tumours (mastocytoma and mast cell sarcoma). Recent studies estimate that 1 in 10,000 people are diagnosed with mastocytosis. Although prompt diagnosis and appropriate management are crucial, little is known about the natural history and currently there are no established management guidelines...
August 3, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28769983/4-month-omalizumab-efficacy-outcomes-for-severe-allergic-asthma-the-dutch-national-omalizumab-in-asthma-registry
#9
S M Snelder, E J M Weersink, G J Braunstahl
BACKGROUND: Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician's global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also, there are no established criteria for identifying patients who will respond to omalizumab based on pre-treatment characteristics. The Dutch National Omalizumab in Asthma Registry was developed in 2011 to better evaluate inclusion criteria and measure treatment response after 4 months...
2017: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/28762062/sequential-rituximab-and-omalizumab-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-syndrome
#10
REVIEW
David Aguirre-Valencia, Iván Posso-Osorio, Juan-Carlos Bravo, Fabio Bonilla-Abadía, Gabriel J Tobón, Carlos A Cañas
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is a small vessel vasculitis associated with eosinophilia and asthma. Clinical manifestations commonly seen in patients presenting with EGPA range from upper airway and lung involvement to neurological, cardiac, cutaneous, and renal manifestations. Treatment for severe presentations includes steroids, cyclophosphamide, plasmapheresis, and recently, rituximab. Rituximab is associated with a good response in the treatment of vasculitis, but a variable response for the control of allergic symptoms...
July 31, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28752720/effects-of-omalizumab-treatment-on-serum-cytokine-concentrations-of-atopic-patients-with-chronic-spontaneous-urticaria-a-preliminary-report
#11
A Sellitto, U De Fanis, A Balestrieri, A Savoia, C Astarita, C Romano
Omalizumab has recently obtained indication for chronic spontaneous urticaria both in the US and Europe. However, the mechanism of action of this drug has yet to be fully elucidated. Previous studies have shown elevations in cytokine serum levels in patients with chronic spontaneous urticaria, and it is not known whether omalizumab treatment may affect cytokine serum levels in this condition. Besides, a proportion of chronic spontaneous urticaria patients have concomitant atopy, which may be associated, at least in theory, with prevalence of serum Th2-type cytokines...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28752717/justification-for-ige-as-a-therapeutic-target-in-chronic-spontaneous-urticaria
#12
M Sánchez-Borges, A Capriles-Hulet, F Caballero-Fonseca, L González-Aveledo
Monoclonal anti-IgE antibodies (omalizumab) are able to induce clinically significant benefits in patients with severe chronic spontaneous urticaria (CS). Those results led clinicians and investigators to reconsider a possible pathogenic role not previously supported for IgE and its receptors in this disease, and to investigate additional approaches for understanding its pathogenesis. IgE antibodies to unknown environmental allergens able to trigger chronic urticaria are not generally regarded as the etiologic factor for the disease...
July 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28751232/omalizumab-treatment-in-chronic-inducible-urticaria-a-systematic-review-of-published-evidence
#13
Marcus Maurer, Martin Metz, Randolf Brehler, Uwe Hillen, Thilo Jakob, Vera Mahler, Claudia Pföhler, Petra Staubach, Regina Treudler, Bettina Wedi, Markus Magerl
BACKGROUND: Omalizumab, a recombinant anti-IgE antibody, effectively treats chronic spontaneous urticaria. Evidence is lacking in chronic inducible urticarias (CIndUs), which are frequently H1-antihistamine resistant. OBJECTIVE: We aimed to determine, from the current published literature, the strength of evidence for omalizumab efficacy and safety in the treatment of CIndUs. METHODS: We performed a PubMed® search to identify evidence on omalizumab use in the following nine CIndU subtypes: symptomatic dermographism, cold urticaria, delayed pressure urticaria, solar urticaria, heat urticaria, vibratory angioedema, cholinergic urticaria, contact urticaria and aquagenic urticaria...
July 24, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28748365/urticaria-and-angioedema-an-update-on-classification-and-pathogenesis
#14
REVIEW
Susanne Radonjic-Hoesli, Kathrin Scherer Hofmeier, Sara Micaletto, Peter Schmid-Grendelmeier, Andreas Bircher, Dagmar Simon
Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or both. In the last years, urticaria has increasingly attracted notice to clinicians and researchers, last but not least inspired by the approval of omalizumab, an anti-IgE antibody, for urticaria treatment. There is wide consensus on the clinical classification based on duration and elicitation. However, the pathogenesis is incompletely understood. This review summarizes current guidelines for the management and novel insights in the pathogenesis of urticaria with special focus on their impact on clinical praxis...
July 26, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28747843/omalizumab-s-role-in-the-treatment-of-steroid-dependent-malignant-idiopathic-anaphylaxis
#15
Öner Özdemir, Hayrunnisa Bekis Bozkurt, Bahri Elmas
If an anaphylaxis episode is not caused by an identifiable trigger, it is defined as idiopathic anaphylaxis. Although it is rarely observed, idiopathic anaphylaxis is clinically significant because of its morbidity and fatality risk. No effective treatment has been demonstrated to date. We report a girl aged 16 years who had had malignant idiopathic anaphylaxis since the age of 12 years who was treated successfully with omalizumab. Although she avoided allergic trigger foods such as tomato and seafood, she used to have these attacks twice a week...
June 2017: Türk Pediatri Arşivi
https://www.readbyqxmd.com/read/28734860/the-expanding-field-of-biologics-in-the-management-of-chronic-urticaria
#16
Shyam Joshi, David A Khan
Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab...
July 19, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28725641/mechanisms-mediating-pediatric-severe-asthma-and-potential-novel-therapies
#17
REVIEW
Aldara Martin Alonso, Sejal Saglani
Although a rare disease, severe therapy-resistant asthma in children is a cause of significant morbidity and results in utilization of approximately 50% of health-care resources for asthma. Improving control for children with severe asthma is, therefore, an urgent unmet clinical need. As a group, children with severe asthma have severe and multiple allergies, steroid resistant airway eosinophilia, and significant structural changes of the airway wall (airway remodeling). Omalizumab is currently the only add-on therapy that is licensed for use in children with severe asthma...
2017: Frontiers in Pediatrics
https://www.readbyqxmd.com/read/28722454/-chronic-urticaria-new-views-on-diagnosis-and-treatment-of-disease
#18
Dana Prusíková
Interest in chronic urticaria has grown in recent years, largely owing to the advent of new modes treatment especially in the form of the biologic preparation omalizumab. New scientific and clinical findings have not only facilitated a more comprehensive view of the disease but have streamlined the classification and diagnostic approach as well. Diagnostics are no longer burdened by cumbersome and lengthy investigative procedures into the etiology of urticaria, but are much more rapid and targeted bringing about more timely relief of the patient's symptoms...
2017: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/28721017/targeted-therapy-in-severe-asthma-today-focus-on-immunoglobulin-e
#19
REVIEW
Girolamo Pelaia, Giorgio Walter Canonica, Andrea Matucci, Rossella Paolini, Massimo Triggiani, Pierluigi Paggiaro
Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard "one size fits all" approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed for asthma, which has the potential to guide treatment decisions. Among the many asthma phenotypes, allergic asthma represents the widest and most easily recognized asthma phenotype, present in up to two-thirds of adults with asthma...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28720253/pulmonary-actinomycosis-in-a-patient-with-chronic-eosinophilic-pneumonia-treated-with-omalizumab
#20
Marta Erro Iribarren, Carolina Cisneros Serrano, Olga Rajas Naranjo, Elena García Castillo
No abstract text is available yet for this article.
July 15, 2017: Archivos de Bronconeumología
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"